Ilex Says Clofarabine Will Go To Oncologic Advisory Committee Dec. 1
This article was originally published in The Pink Sheet Daily
The announcement follows FDA’s three-month extension of clofarabine’s review deadline. The pediatric leukemia agent is presumably one of two drugs scheduled for review by the Oncologic Drugs Advisory Committee on Dec. 1.
You may also be interested in...
The sponsors are seeking a monotherapy indication for treatment of relapsed aggressive non-Hodgkin’s lymphoma in patients previously treated with at least two combination chemotherapy regimens. The NDA's user fee date is Jan. 15.
Ilex submits data on 14 additional patients with acute lymphoblastic and acute myeloid leukemia to FDA, extending the user fee date by three months to Dec. 30. The company completed the original rolling NDA March 29.
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.